506 related articles for article (PubMed ID: 24738483)
41. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.
Ćalasan MB; Wulffraat NM
Expert Rev Clin Immunol; 2014 Jul; 10(7):843-54. PubMed ID: 24857620
[TBL] [Abstract][Full Text] [Related]
42. Children with juvenile idiopathic arthritis frequently experience interruptions to their medical therapy.
Kazamia K; Holmquist L; Fagerlund A; Berntson L
Acta Paediatr; 2014 May; 103(5):529-36. PubMed ID: 24517256
[TBL] [Abstract][Full Text] [Related]
43. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis.
Huang JL; Hung IJ; Hsieh KH
Asian Pac J Allergy Immunol; 1997 Jun; 15(2):71-5. PubMed ID: 9346269
[TBL] [Abstract][Full Text] [Related]
44. Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections.
Brown GT; Wright FV; Lang BA; Birdi N; Oen K; Stephens D; McComas J; Feldman BM
Arthritis Rheum; 2005 Dec; 53(6):897-904. PubMed ID: 16342103
[TBL] [Abstract][Full Text] [Related]
45. Systemic adverse events following intraarticular corticosteroid injections for the treatment of juvenile idiopathic arthritis: two patients with dermatologic adverse events and review of the literature.
Goldzweig O; Carrasco R; Hashkes PJ
Semin Arthritis Rheum; 2013 Aug; 43(1):71-6. PubMed ID: 23332901
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Ravelli A; Caria MC; Buratti S; Malattia C; Temporini F; Martini A
J Rheumatol; 2001 Apr; 28(4):865-7. PubMed ID: 11327264
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan.
Mori M; Naruto T; Imagawa T; Murata T; Takei S; Tomiita M; Itoh Y; Fujikawa S; Yokota S
Mod Rheumatol; 2009; 19(1):1-11. PubMed ID: 18815725
[TBL] [Abstract][Full Text] [Related]
48. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
Khawaja K; Al-Maini M
Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
[TBL] [Abstract][Full Text] [Related]
49. A case of juvenile idiopathic arthritis exhibiting repair of systemic bone erosion in response to continuation of MTX therapy after achievement of clinical remission.
Nakatani T; Maekawa T; Ishii S
Mod Rheumatol; 2011 Oct; 21(5):514-7. PubMed ID: 21331659
[TBL] [Abstract][Full Text] [Related]
50. Recommendations for the use of methotrexate in juvenile idiopathic arthritis.
Niehues T; Lankisch P
Paediatr Drugs; 2006; 8(6):347-56. PubMed ID: 17154642
[TBL] [Abstract][Full Text] [Related]
51. Juvenile idiopathic arthritis overview and involvement of the temporomandibular joint: prevalence, systemic therapy.
Carrasco R
Oral Maxillofac Surg Clin North Am; 2015 Feb; 27(1):1-10. PubMed ID: 25483440
[TBL] [Abstract][Full Text] [Related]
52. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.
DeWitt EM; Kimura Y; Beukelman T; Nigrovic PA; Onel K; Prahalad S; Schneider R; Stoll ML; Angeles-Han S; Milojevic D; Schikler KN; Vehe RK; Weiss JE; Weiss P; Ilowite NT; Wallace CA;
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1001-10. PubMed ID: 22290637
[TBL] [Abstract][Full Text] [Related]
53. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.
Correll CK; Binstadt BA
Pediatr Res; 2014 Jan; 75(1-2):176-83. PubMed ID: 24213625
[TBL] [Abstract][Full Text] [Related]
54. In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?
Roszkiewicz J; Smolewska E
Curr Rheumatol Rep; 2017 Apr; 19(4):19. PubMed ID: 28361333
[TBL] [Abstract][Full Text] [Related]
55. Advanced therapy for juvenile arthritis.
Murray KJ; Lovell DJ
Best Pract Res Clin Rheumatol; 2002 Jul; 16(3):361-78. PubMed ID: 12387805
[TBL] [Abstract][Full Text] [Related]
56. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies.
Pardeo M; Bracaglia C; De Benedetti F
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):505-516. PubMed ID: 29773270
[TBL] [Abstract][Full Text] [Related]
57. [Current therapy of polyarticular forms of juvenile idiopathic arthritis].
Hospach A; Rühlmann JM; Weller-Heinemann F
Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055
[TBL] [Abstract][Full Text] [Related]
58. Leflunomide in systemic onset Juvenile idiopathic arthritis.
Jahan A; Dewan V; Yadav TP
Indian Pediatr; 2012 Sep; 49(9):750-2. PubMed ID: 23024081
[TBL] [Abstract][Full Text] [Related]
59. Systemic Juvenile Idiopathic Arthritis.
Lee JJY; Schneider R
Pediatr Clin North Am; 2018 Aug; 65(4):691-709. PubMed ID: 30031494
[TBL] [Abstract][Full Text] [Related]
60. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
Pagnini I; Bertini F; Cimaz R
Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
